Transplant oncology and anti-cancer immunosuppressants
Organ transplantation is a life-saving intervention that enhances the quality of life for patients with end-stage organ failure. However, long-term immunosuppressive therapy is required to prevent allogeneic graft rejection, which inadvertently elevates the risk of post-transplant malignancies, espe...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1520083/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556626248564736 |
|---|---|
| author | Dejun Kong Jinliang Duan Shaofeng Chen Zhenglu Wang Zhenglu Wang Jiashu Ren Jianing Lu Tao Chen Zhuolun Song Di Wu Yuan Chang Zhongqian Yin Zhongyang Shen Zhongyang Shen Zhongyang Shen Zhongyang Shen Hong Zheng Hong Zheng Hong Zheng Hong Zheng |
| author_facet | Dejun Kong Jinliang Duan Shaofeng Chen Zhenglu Wang Zhenglu Wang Jiashu Ren Jianing Lu Tao Chen Zhuolun Song Di Wu Yuan Chang Zhongqian Yin Zhongyang Shen Zhongyang Shen Zhongyang Shen Zhongyang Shen Hong Zheng Hong Zheng Hong Zheng Hong Zheng |
| author_sort | Dejun Kong |
| collection | DOAJ |
| description | Organ transplantation is a life-saving intervention that enhances the quality of life for patients with end-stage organ failure. However, long-term immunosuppressive therapy is required to prevent allogeneic graft rejection, which inadvertently elevates the risk of post-transplant malignancies, especially for liver transplant recipients with a prior history of liver cancer. In response, the emerging field of transplant oncology integrates principles from oncology and immunology to improve outcomes for patients at high risk of tumor occurrence or recurrence following transplantation. Therefore, it is of substantial clinical significance to develop immunosuppressants that possess both immunosuppressive and anti-tumor properties. For instance, mTOR inhibitors demonstrate anti-tumor effects among antimetabolite immunosuppressive drugs, and recent studies indicate that capecitabine, an antimetabolite chemotherapeutic, may also exhibit immunosuppressive activity in the clinic for liver transplants suffering from hepatocellular carcinoma. This review systematically explores potential immunosuppressants with dual anti-tumor and immunosuppressive effects to support the management of transplant patients at elevated risk of tumor occurrence or recurrence. |
| format | Article |
| id | doaj-art-25f19db6c5974199a4b4b2686b06c4a3 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-25f19db6c5974199a4b4b2686b06c4a32025-01-07T06:47:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15200831520083Transplant oncology and anti-cancer immunosuppressantsDejun Kong0Jinliang Duan1Shaofeng Chen2Zhenglu Wang3Zhenglu Wang4Jiashu Ren5Jianing Lu6Tao Chen7Zhuolun Song8Di Wu9Yuan Chang10Zhongqian Yin11Zhongyang Shen12Zhongyang Shen13Zhongyang Shen14Zhongyang Shen15Hong Zheng16Hong Zheng17Hong Zheng18Hong Zheng19Nankai University School of Medicine, Tianjin, ChinaNankai University School of Medicine, Tianjin, ChinaNankai University School of Medicine, Tianjin, ChinaTianjin Organ Transplantation Research Center, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, ChinaKey Laboratory of Transplant Medicine, Chinese Academy of Medical Sciences, Tianjin, ChinaTianjin First Central Clinical College, Tianjin, ChinaTianjin First Central Clinical College, Tianjin, ChinaNankai University School of Medicine, Tianjin, ChinaTianjin Organ Transplantation Research Center, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, ChinaTianjin Organ Transplantation Research Center, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, ChinaNankai University School of Medicine, Tianjin, ChinaTianjin First Central Clinical College, Tianjin, ChinaTianjin Organ Transplantation Research Center, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, ChinaKey Laboratory of Transplant Medicine, Chinese Academy of Medical Sciences, Tianjin, ChinaResearch Institute of Transplant Medicine, Nankai University, Tianjin, ChinaTianjin Key Laboratory for Organ Transplantation, Tianjin, ChinaTianjin Organ Transplantation Research Center, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, ChinaKey Laboratory of Transplant Medicine, Chinese Academy of Medical Sciences, Tianjin, ChinaResearch Institute of Transplant Medicine, Nankai University, Tianjin, ChinaTianjin Key Laboratory for Organ Transplantation, Tianjin, ChinaOrgan transplantation is a life-saving intervention that enhances the quality of life for patients with end-stage organ failure. However, long-term immunosuppressive therapy is required to prevent allogeneic graft rejection, which inadvertently elevates the risk of post-transplant malignancies, especially for liver transplant recipients with a prior history of liver cancer. In response, the emerging field of transplant oncology integrates principles from oncology and immunology to improve outcomes for patients at high risk of tumor occurrence or recurrence following transplantation. Therefore, it is of substantial clinical significance to develop immunosuppressants that possess both immunosuppressive and anti-tumor properties. For instance, mTOR inhibitors demonstrate anti-tumor effects among antimetabolite immunosuppressive drugs, and recent studies indicate that capecitabine, an antimetabolite chemotherapeutic, may also exhibit immunosuppressive activity in the clinic for liver transplants suffering from hepatocellular carcinoma. This review systematically explores potential immunosuppressants with dual anti-tumor and immunosuppressive effects to support the management of transplant patients at elevated risk of tumor occurrence or recurrence.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1520083/fullorgan transplantationtransplant oncologyimmunosuppressantanti-metabolic drugsanti-tumor |
| spellingShingle | Dejun Kong Jinliang Duan Shaofeng Chen Zhenglu Wang Zhenglu Wang Jiashu Ren Jianing Lu Tao Chen Zhuolun Song Di Wu Yuan Chang Zhongqian Yin Zhongyang Shen Zhongyang Shen Zhongyang Shen Zhongyang Shen Hong Zheng Hong Zheng Hong Zheng Hong Zheng Transplant oncology and anti-cancer immunosuppressants Frontiers in Immunology organ transplantation transplant oncology immunosuppressant anti-metabolic drugs anti-tumor |
| title | Transplant oncology and anti-cancer immunosuppressants |
| title_full | Transplant oncology and anti-cancer immunosuppressants |
| title_fullStr | Transplant oncology and anti-cancer immunosuppressants |
| title_full_unstemmed | Transplant oncology and anti-cancer immunosuppressants |
| title_short | Transplant oncology and anti-cancer immunosuppressants |
| title_sort | transplant oncology and anti cancer immunosuppressants |
| topic | organ transplantation transplant oncology immunosuppressant anti-metabolic drugs anti-tumor |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1520083/full |
| work_keys_str_mv | AT dejunkong transplantoncologyandanticancerimmunosuppressants AT jinliangduan transplantoncologyandanticancerimmunosuppressants AT shaofengchen transplantoncologyandanticancerimmunosuppressants AT zhengluwang transplantoncologyandanticancerimmunosuppressants AT zhengluwang transplantoncologyandanticancerimmunosuppressants AT jiashuren transplantoncologyandanticancerimmunosuppressants AT jianinglu transplantoncologyandanticancerimmunosuppressants AT taochen transplantoncologyandanticancerimmunosuppressants AT zhuolunsong transplantoncologyandanticancerimmunosuppressants AT diwu transplantoncologyandanticancerimmunosuppressants AT yuanchang transplantoncologyandanticancerimmunosuppressants AT zhongqianyin transplantoncologyandanticancerimmunosuppressants AT zhongyangshen transplantoncologyandanticancerimmunosuppressants AT zhongyangshen transplantoncologyandanticancerimmunosuppressants AT zhongyangshen transplantoncologyandanticancerimmunosuppressants AT zhongyangshen transplantoncologyandanticancerimmunosuppressants AT hongzheng transplantoncologyandanticancerimmunosuppressants AT hongzheng transplantoncologyandanticancerimmunosuppressants AT hongzheng transplantoncologyandanticancerimmunosuppressants AT hongzheng transplantoncologyandanticancerimmunosuppressants |